4.5 Editorial Material

Interplay between Klebsiella pneumoniae producing KPC-31 and KPC-3 under treatment with high dosage meropenem: a case report

出版社

SPRINGER
DOI: 10.1007/s10096-021-04388-y

关键词

Klebsiella pneumoniae; Ceftazidime-avibactam; KPC

资金

  1. Sapienza University of Rome [RM11916B6A8B5F8D]

向作者/读者索取更多资源

The aim of this study was to investigate ceftazidime-avibactam resistant and susceptible Klebsiella pneumoniae strains isolated from a patient with SARS-CoV2. The patient's condition, antimicrobial therapies, and microbiological data were collected. The study found the presence of highly conserved ST2502 strains producing KPC-31 and KPC-3, selected by CZA and carbapenem treatments, respectively, in the patient.
The objective was to study ceftazidime-avibactam resistant and susceptible Klebsiella pneumoniae isolated from a patient admitted to the Policlinico Umberto I of Rome for SARS-CoV2. Data on the evolution of patient's conditions, antimicrobial therapies, and microbiological data were collected. Whole-genome sequencing performed by Illumina and Nanopore sequencing methods were used to type the strains. During the hospitalization, a SARS-CoV2-infected patient was colonized by a KPC-producing K. pneumoniae strain and empirically treated with ceftazidime-avibactam (CZA) when presenting spiking fever symptoms. Successively, ST2502 CZA-resistant strain producing the KPC-31 variant gave a pulmonary infection to the patient. The infection was treated with high doses of meropenem. The KPC-31-producing strain disappeared but the patient remained colonized by a KPC-3-producing K. pneumoniae strain. An interplay between highly conserved KPC-31- and KPC-3-producing ST2502 strains occurred in the SARS-CoV2 patient during the hospitalization, selected by CZA and carbapenem treatments, respectively.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据